Abbott Laboratories Fined

Article

FDA imposes $100 million fine

Abbott Park, Ill-Abbott Laboratories has been fined $100 million by the Food and Drug Administration. The two organizations entered into a consent decree, which does not represent an admission of any violation, but prohibits Abbott from manufacturing or distributing diagnostic products until their Lake County, Ill, manufacturing site conforms with the FDA's Quality System Regulation. The deadline for compliance is one year.

The original decree allowed the products to remain on the market for 30 days, so consumers would have time to find alternate suppliers. However, the US District Court amended the decree upon the request of users and extended the deadline to January 10, 2000. "This decree allows us to resolve these issues comprehensively and systematically without disruption to patient care worldwide. We will work closely and cooperatively with the FDA to ensure our Lake County, Ill, diagnostic manufacturing operations are in full and complete conformance as rapidly as possible," states Miles D. White, chairman and chief executive officer of Abbott Laboratories. The decree does not affect other Abbott products.

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
COVID-19 infection (Adobe Stock327378972 by rost9)
Swarm of Mosquitoes on Green Background Disease Carriers Insect Infestation  (Adobe Stock 1609688034 by Amith)
Structural detail of Hepatitis B virus on blue-green background. 3D illustration (Adobe Stock 239268660 by Destina)
© 2025 MJH Life Sciences

All rights reserved.